Pharmaceutical Technology

MARCH 30, 2023

The breakthrough drug is predicted to be a blockbuster, generating total forecast sales of $12.9bn between 2023 and 2028. The FDA’s decision on Leqembi was based on data from a Phase II clinical trial named Athena AD. Leqembi is forecast to generate total sales of $12.9bn worldwide between 2023 and 2028.

Sales 130

Sales Drugs Antibody FDA Approval 130

Fierce Pharma

MAY 2, 2024

. | Sanofi and Regeneron’s highly anticipated approval of Dupixent to treat COPD could be delayed, as the FDA has requested additional efficacy data from two trials. The regulatory hurdle comes as Eylea showed stagnant sales, even though its new high-dose formula is seeing increased uptake.

Sales 68

Sales Trials 68

pharmaphorum

FEBRUARY 27, 2024

Europe's commercial leaders are gearing up for a faster trial-to-treatment pathway, leveraging CRM technology to empower HCPs and sales teams.

Trials 115

Trials Sales 115

Bio Pharma Dive

JANUARY 29, 2024

An under-the-skin Opdivo shot produced similar results to an intravenous formulation in kidney cancer, giving Bristol Myers a chance at sustaining sales past a key patent expiration in 2028.

Sales 168

Sales Trials 168

Fierce Pharma

FEBRUARY 6, 2024

On a day when Vertex revealed trial data that indicate | On a day when Vertex revealed trial data that indicate its next-generation cystic fibrosis (CF) treatment will soon be ready to grab the baton, the Boston company also presented figures that show Trikafta remains formidable. billion in sales, bringing its 2023 haul to $8.9

Sales 84

Sales Trials 84

pharmaphorum

NOVEMBER 18, 2022

Gene-testing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The post After disappointing trial, Editas puts lead CRISPR drug up for sale appeared first on.

Sales 92

Sales Trials In-Vivo Gene Editing 92

Bio Pharma Dive

AUGUST 3, 2023

The company disclosed the study result alongside second quarter earnings showing Lumakras sales were flat versus the same period one year prior.

Sales 246

Sales Trials Drugs 246

Fierce Pharma

NOVEMBER 14, 2023

As a result, Leerink Partners has slashed its sales projections for the nonsteroidal topical treatment. In the market, however, Vtama is struggling to catch on.

Sales 80

Sales Trials Marketing 80

Bio Pharma Dive

JULY 19, 2022

The setback slows plans to broaden use of a drug that analysts expect to generate nearly $10 billion in annual sales later this decade.

Trials 263

Trials Sales Drugs 263

Bio Pharma Dive

MARCH 12, 2024

The setback shuts out Acadia’s top medicine from a large sales opportunity and heightens the biotech’s dependence on a pipeline filled with risky drug prospects.

Drugs 118

Drugs Sales Trials Medicine 118

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 14, 2022

The medical devices industry in the country has sought the Centre to define online and offline mode of sale, provide more clarity on the regulations that are binding the online sales and suggested inclusion of online medical devices players under the Uniform Code for Medical Devices Marketing Practices (UCMDMP).

Sales 129

Sales Regulation Marketing Drugs 129

pharmaphorum

FEBRUARY 18, 2022

Bayer now says it expects to make €3 billion in sales for its prostate cancer treatment Nubeqa, up from an earlier estimate of €1 billion, after reviewing new data for the drug in metastatic hormone-sensitive tumours. The post Bayer triples sales forecast for prostate cancer drug Nubeqa appeared first on.

Sales 98

Sales Drugs Hormones Pharma Production 98

Pharmaceutical Technology

DECEMBER 4, 2023

in tiered royalties on worldwide sales of Qtorin rapamycin. Palvella will receive $5m as an upfront payment, with Ligand getting 8%-9.8%

Sales 130

Sales Trials 130

Bio Pharma Dive

FEBRUARY 23, 2023

The biotech expects to earn at least $5 billion from sales of its COVID vaccine this year, which would be about one-third of what it made in 2022.

Trials 168

Trials Sales Vaccination Vaccine 168

pharmaphorum

APRIL 27, 2022

GlaxoSmithKline has made a promising start to 2022 with a 32% rise in group sales, albeit measured against a downbeat first-quarter result in 2021. billion with no sales recorded in the prior year. Vir Biotechnology-partnered COVID-19 antibody Xevudy (sotrovimab) was the big contributor to the improved result, adding £1.3 billion ($1.6

Sales 97

Sales Antibody Vaccination Vaccine 97

pharmaphorum

DECEMBER 23, 2022

Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer. In 2023, omnichannel behaviours will directly influence incentive compensation models by correlating successful engagement data to successful sales outcomes.

Sales 105

Sales Marketing Life Science Compliance 105

BioTech 365

NOVEMBER 2, 2021

2021 Danyelza Patent, Sales & Clinical Trials Outlook Report to 2028 – ResearchAndMarkets.com 2021 Danyelza Patent, Sales & Clinical Trials Outlook Report to 2028 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Danyelza Patent, Sales & Clinical Trials Outlook 2028” report has been added … (..)

Clinical Trials 40

Clinical Trials Clinical Trials Sales Trials 40

BioTech 365

NOVEMBER 3, 2021

Ayvakit Patent, Sales & Clinical Trials Market Insight Report 2021-2028 – ResearchAndMarkets.com Ayvakit Patent, Sales & Clinical Trials Market Insight Report 2021-2028 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Ayvakit Patent, Sales & Clinical Trials Insight 2028” report has been added to (..)

Clinical Trials 40

Clinical Trials Clinical Trials Sales Marketing 40

XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

pharmaphorum

FEBRUARY 9, 2022

There was another £447 million from sales of GSK’s adjuvant, used to boost the efficacy of other companies’ COVID-19 shots, although the company’s own efforts to develop a jab have so far been unsuccessful. Last year, sales at the JV stabilised at £9.6 billion, but still came in ahead of analyst expectations.

Sales 105

Sales Production Vaccination Vaccine 105

Bio Pharma Dive

MARCH 10, 2021

and European regulators in hopes of resuming study of the treatment as well as sales of a related product. The biotech is discussing its findings with U.S.

Gene Therapy 271

Gene Therapy Gene Sales Regulation 271

pharmaphorum

AUGUST 6, 2021

billion from sales of just under 200 million doses of its COVID-19 vaccine, taking its tally since approval to around $6 billion from 302 million shots. Moderna is now predicting sales of $20 billion for 2021 as a whole from up to 1 billion doses delivered, which compares to Pfizer estimate of $33.5 Moderna made a massive $4.2

Sales 105

Sales Vaccination Vaccine Antibody 105

Pharmaceutical Technology

OCTOBER 30, 2022

Undefined’s ionic propulsion drone has completed an outside flying test and plans to go on sale in 2024. The post Undefined Trials eVTOL Ion Propulsion Drone appeared first on Pharmaceutical Technology. Outlook: The industry for drone logistics and shipping is expanding rapidly. This article was originally published in Verdict.co.uk.

Trials 130

Trials Sales Research 130

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 11, 2024

The Drugs Technical Advisory Board (DTAB) of the Union health ministry has once again recommended prohibiting the manufacture, sale and distribution of pain relief drug combination S(+) etodolac+paracetamol, after considering a sub-committee report.

Manufacturing 205

Manufacturing Sales Drugs Clinical Trials 205

XTalks

APRIL 5, 2024

Amylyx Pharmaceuticals announced yesterday that it will be pulling its ALS (amyotrophic lateral sclerosis) drug Relyvrio from the market after failing in a confirmatory trial. Last month, Amylyx reported results from the global PHOENIX Phase III clinical trial that were unable to confirm the drug’s effectiveness.

Trials 98

Trials Drugs Marketing FDA Approval 98

BioTech 365

AUGUST 5, 2021

Billion EZH2 Inhibitor Market Opportunity, Sales & Clinical Trials Insights to 2026 – ResearchAndMarkets.com Global $1.2

Clinical Trials 40

Clinical Trials Clinical Trials Sales Marketing 40

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1 mRNA ambitions.

Sales 100

Sales Vaccination Vaccine Drugs 100

pharmaphorum

JULY 27, 2022

” Sales of the vaccine more than doubled to £731 million in the quarter due in part to a recovery demand following the easing of COVID-19 restrictions, inventory building in the US and strong demand in Germany. GSK’s HIV business, run through joint venture company ViiV Healthcare, also had a good quarter with sales up 14% to £1.4

Sales 52

Sales Vaccination Vaccine Medicine 52

Drug Discovery World

JUNE 1, 2023

Sales of branded anti-obesity drugs (AOB) could hit $44 billion in 2030 vs $2.5 Bloomberg Intelligence’s model only includes approved drugs and those in ongoing Phase III trials. The post Market analysts predict $44 billion in obesity drug sales in 2030 appeared first on Drug Discovery World (DDW).

Sales 52

Sales Marketing Drugs Branding 52

Pharmaceutical Technology

MARCH 28, 2023

5 adapted bivalent Covid-19 vaccine, the company has forecasted a slump in sales for 2023 as Covid-19 vaccine demand falls. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9% In December 2022, BioNTech initiated a Phase I clinical trial of BNT163 – an HSV vaccine candidate.

Vaccination 276

Vaccination Vaccine Development Clinical Trials 276

Bio Pharma Dive

FEBRUARY 16, 2021

The biotech is also suspending sales of its related treatment Zynteglo following a leukemia diagnosis in a clinical trial volunteer and a case of a cancer-like bone marrow disease in another.

Gene Therapy 302

Gene Therapy Gene Clinical Trials Clinical Trials 302

Cloudbyz

MARCH 24, 2022

Cloudbyz and Salesforce Join Together for Clinical Trial Solutions Partner Enablement Event.

Sales 52

Sales Life Science Clinical Trials Clinical Trials 52

BioTech 365

AUGUST 23, 2021

European Biosimilars Market, Dosage, Price, Sales & Clinical Trials Insight 2026: European Market to Surpass $10 Billion by 2026 – ResearchAndMarkets.com European Biosimilars Market, Dosage, Price, Sales & Clinical Trials Insight 2026: European Market to Surpass $10 Billion by 2026 … Continue reading →

Clinical Trials 40

Clinical Trials Clinical Trials Sales Marketing 40

BioTech 365

FEBRUARY 3, 2021

Global Cancer Biological Toxins Drug Market (2020 to 2026) – Opportunity, Drug Sales & Clinical Trials Insight – ResearchAndMarkets.com Global Cancer Biological Toxins Drug Market (2020 to 2026) – Opportunity, Drug Sales & Clinical Trials Insight – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The … (..)

Clinical Trials 40

Clinical Trials Clinical Trials Sales Marketing 40

Bio Pharma Dive

JULY 9, 2021

Zynteglo sales have been on hold since February, when a patient in a clinical trial of another, related Bluebird medicine developed leukemia.

Gene Therapy 263

Gene Therapy Gene Marketing Clinical Trials 263

Fierce Pharma

NOVEMBER 2, 2023

Earlier this week, the company said that a pivotal trial on the medicine failed to reach its primary endpoint. The third quarter marked a momentous one for Sarepta Therapeutics, bringing the long-anticipated launch of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys.

Gene Therapy 98

Gene Therapy Gene Sales Medicine 98

XTalks

JANUARY 29, 2021

Several oncology products now have “blockbuster” status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products. Keytruda (Pembrolizumab) and Opdivo (Nivolumab).

Clinical Trials 104

Clinical Trials Clinical Trials Production Trials 104